Efficacy and Pharmacodynamic Study of Panzem速 NCD in Patients With Hormone-Refractory Prostate Cancer
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacokinetics, of Panzem速 NCD in patients with metastatic, docetaxel refractory, androgen-independent prostate cancer.
Prostate Cancer
DRUG: Panzem速 NCD
6 month progression free survival, at time of progression
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacokinetics, of Panzem速 NCD in patients with metastatic, docetaxel refractory, androgen-independent prostate cancer.